Colorectal Cancer

Trial results support 5.4 mg/kg of trastuzumab deruxtecan as the optimal dose in individuals with HER2+ metastatic colorectal cancer.

Prediagnostic weight loss could be an important marker for colorectal cancer diagnosis.

Experts note that pharmacists are well positioned to play a key role in precision oncology and molecular tumor boards.

Research has even shown that cancer diagnosis can be significantly improved using AI, with real-time data updates, personalized attention, and ultimately better results at lower costs.

The patient's list of medications reveals significant drug interactions to be addressed.

Patients who received first-line ICI showed a significant improvement in progression-free survival (PFS) and overall survival (OS) compared to chemotherapy treatment.

This is the first indication for tucatinib that extends beyond the treatment of advanced unresectable or metastatic HER2-positive breast cancer.

The stool-test is the first-of-its-kind to detect CRC in adults aged 45 to 49 years, with a premarket approval submission planned to be sent to the FDA early in 2023.

The findings show promising clinical activity and a favorable tolerability profile in the treatment of KRASG12C-mutated advanced colorectal cancer.

The opportunity to provide non-invasive colorectal cancer screening and education to patients is undoubtedly a role that pharmacists can fill.

The protein is vitally important and could be a prognostic indicator and potential therapeutic target.

Identifying how survivors adjust to their cancer may help health care providers provide tailored self-management skills.

Regular physical activity helps to facilitate a healthy gut microbiome and lowers inflammation, which were observed in patients independent of body mass index.

A recent study did not find a significant association between a healthy plant-based diet and the risk for colorectal cancer among 93,475 US women.

Nearly 8 out of 10 individuals within the recommended age range for colorectal cancer screening are considered to have an average risk for the disease.

By 2019, lung cancer mortality rates decreased by 5.4% in males since 2015, while deaths from ovary cancer have also declined rapidly over the past 2 decades.

Patients with synchronous liver metastases from colorectal cancer have been found to have worse outcomes than those with metachronous liver metastases.

Bevacizumab-adcd (Vegzelma) is indicated for the treatment of nonsquamous non–small cell lung cancer; recurrent glioblastoma; metastatic colorectal cancer; persistent, recurrent, or metastatic cervical cancer; metastatic renal cell carcinoma; and epithelial ovarian, fallopian tube, or primary peritoneal cancer.

The FDA accepted a supplemental New Drug Application for tucatinib to treat HER2 colorectal cancer, which could significantly improve outcomes for these patients.

Selpercatinib produced clinically meaningful and durable responses across a variety of tumor types in patients with RET-driven cancers.

Study indicates that a diet high in ultra-processed food is more likely to increase the risk of colorectal cancer in men than it is women.

Therapy shows positive clinical efficacy and favorable tolerability as a monotherapy and in combination with cetuximab in heavily pretreated patients who have a KRASG12C mutation.

Fruquintinib reduced the risk of death in patients with advanced metastatic colorectal cancer by 34% and led to longer overall survival than among those given placebo.

Processed meats and products high in added sugars and low in fiber contribute to weight gain and obesity, which is an established risk factor.

Scientists found that inhibiting certain immune system receptors could treat colon cancer and other diseases of the gastrointestinal tract.

Gamma-delta T-cells undergo a biochemical change that leads them to spur the growth of tumors that previously restricted.

Delayed diagnosis in younger individuals and presentation of advanced disease highlights need for awareness.

The results showed a 38.1% confirmed objective response rate among HER2-positive patients who received tucatinib in combination with trastuzumab.

Analysis shows that the common infection may be a driver of the disease in adults younger than aged 50 years.

Screening participation increased over time, but the increase was smallest among individuals aged 50 to 54.